NCT00130442 - Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma | Biotech Hunter

Enrollment

134

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions

Melanoma

Interventions

DRUG

PI-88 and dacarbazine

190 mg daily by subcutaneous injection for PI-88 and 1000 mg/m2 on day 1 of each 21 day cycle by intravenous infusion

DRUG

dacarbazine or DTIC

intravenous infusion 1000 mg/m2 on day 1 of every 21 day cycle

Trial Locations (12)

Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown

Westmead Institute for Cancer Research, Sydney

Border Medical Oncology, Wodonga

Wesley Research Institute, Auchenflower

Princess Alexandra Hospital, Woolloongabba

Townsville Cancer Centre, Townsville

The Queen Elizabeth Hospital, Woodville

Royal Perth Hospital, Perth

Sir Charles Gairdner Hospital, Perth

Arizona Cancer Centre, Tucson

University of Colorado Health Science Centre, Denver

Vanderbilt-Ingram Cancer Center, Nashville